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Abstract
Obstructive sleep apnoea (OSA) is one of the most common sleep-related breathing disorders. New epidemiological 
studies show that the disease is much more prevalent in the general population than previously believed. Individuals 
with cardiovascular diseases are a special group of patients suffering from OSA as the prevalence of the disorder among 
them is much greater than in the general population, and it can constitute an isolated risk factor for the development of 
some cardiovascular diseases. This article will discuss methods for diagnosing OSA, its epidemiology among patients 
with particular cardiovascular diseases and the prospects for the development of screening examinations.
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Introduction
Physiological sleep is of fundamental importance for the 
development, regeneration and functioning of the nervous 
system as well as consolidation of memory pathways. It 
helps maintain proper cleansing of neurons which prevents 
later degenerations of the nervous system. It also affects 
the proper functioning of the cardiovascular system, phy-
siological hormonal play, has an impact on the mood and, 
indirectly, on each cell of the body. Sleep-related disorders 
are a multidisciplinary problem which draws the attention 
of an increasing number of researchers. On the one hand, 
lack of proper sleep may reduce the productivity of an 
individual and be a cause of accidents due to impaired 
concentration during the day. On the other hand, disorde-
red architecture of sleep and some of its pathologies are 
a factor favouring the development of serious diseases, 
such as hypertension, atherosclerosis, brain stroke and 
myocardial infarction [1].
Breathing disorders are among the most serious patho-
logies of sleep. The term encompasses a number of con-
ditions characterized by various levels of ventilation disor-
ders. According to the guidelines of the American Academy 
of Sleep Medicine (AASM), which were updated in 2017, 
we can distinguish such disease entities as: obstructive 
sleep apnea syndrome, central sleep apnea syndrome, 
Cheyne-Stokes Respiration, and alveolar hypoventilation 
syndrome [2].
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well as chronic lung diseases and patients in such physio-
logical states as pregnancy [11].
Symptoms of OSA are classically divided into nocturnal 
and diurnal symptoms. Nocturnal symptoms include loud 
and irregular snoring, presence of apnoea during sleep (ob-
served by, for example, the partner), nightmares, frequent 
arousals, difficulties in falling asleep, excessive perspiration 
and nycturia as well as attacks of dyspnoea during sleep. 
During the day, patients can be excessively drowsy (even af-
ter a seemingly good night’s sleep), may observe cognitive 
decline, decreased libido and sexual potency, throat aches, 
drying of mucosa as well as tendency towards depression. 
As mentioned above, obstructive sleep apnoea frequently 
accompanies other diseases, but can also be responsible 
for the development thereof. It has been confirmed that 
OSA is a risk factor for the development of cardiovascular 
diseases, including brain stroke, ischaemic heart disease 
and hypertension. Chronic, intermittent hypoxia may lead 
to activation of the adrenergic and leptinergic system [12] 
and, in consequence, to metabolic disorders and complica-
tions, such as diabetes, obesity and dyslipidemia — regar-
dless of initial obesity [13]. Men suffering from OSA are also 
significantly more likely to experience erectile dysfunction 
[14]. Due to the impairment of cognitive abilities, obstructi-
ve sleep apnoea has a negative impact on psycho physical 
abilities of drivers. OSA has been identified in Directive of 
the European Union of 2014 as one of the most important 
risk factors for car accidents [15].
While diagnosing a patient in whom OSA is suspected, 
the physician should take into account their thorough hi-
story of sleep and sleep disorders and conduct a comple-
te physical examination of the respiratory, circulatory and 
nervous system. If the patient reports symptoms that may 
indicate the occurrence of breathing disorders and risk 
factors are present, they should be referred for a complete 
diagnostic evaluation. In the case of OSA, the evaluation 
includes questionnaires and clinical scales subjectively 
assessing nocturnal and diurnal symptoms as well as an 
examination during which sleep-related breathing disorders 
are recorded. Without an examination consisting in recor-
ding sleep-related breathing disorders, clinical evaluation 
scales are not sufficient to diagnose OSA. For years, poly-
somnography (PSG) has been the gold standard in diagno-
stic evaluation. The examination must be conducted in clini-
cal conditions and be supervised by medical staff. With the 
advancement of technology in the market, portable devices 
(PM, portable monitoring; HSAT, home sleep apnoea test) 
for monitoring sleep-related breathing disorders began to 
appear on the market. Thanks to their simpler design and 
much better availability, they have become useful tools in 
diagnostic evaluation of OSA, and in some cases they are 
sufficient for making the diagnosis. AASM recommends 
that PSG or an examination with the use of an adequate 
portable device be conducted in patients without severe 
Obstructive sleep apnoea (OSA) is one of the most com-
mon sleep-related breathing disorders. It is characterized 
by multiple episodes of complete collapsing or narrowing 
of the upper airway lumen in the absence of impaired fun-
ction of the breathing muscles. They result in a significant or 
complete cessation of airflow in the respiratory tract. Such 
episodes are usually accompanied by a decrease in arte-
rial blood oxygen saturation proportional to the duration of 
apnoea and the degree of airway obstruction. In response 
to hypoxia, the work of breathing muscles intensifies in or-
der to “break through” the increased resistance of the re-
spiratory tract, which usually results in short, unconscious 
arousals from sleep. OSA can only be diagnosed if apnoea 
or shallow breathing last for at least 10 seconds and occur 
5 times an hour during sleep. The number of episodes (of 
apnoea and shallow breathing) per hour is referred to as 
the apnoea–hypopnoea index (AHI). On the basis of this 
index, we can distinguish mild (AHI from 5 to < 15), mode-
rate (AHI from 15 to < 30) and severe (AHI ≥ 30) OSA. Cur-
rently, shallowing of breathing accompanied by arousals is 
also included in the AHI. Scales evaluating sleepiness du-
ring the day, such as the Epworth Sleepiness Scale (ESS), 
are used to determine the severity of the disease; howe-
ver, due to their low sensitivity, their usefulness in clinical 
practice is decreasing.
Epidemiological data are vague, most likely due to poor 
availability of diagnostics as well as insufficient awareness 
of the problem, among both physicians and patients. Based 
on the conducted epidemiological studies, it is estimated 
that the incidence of moderate and severe OSA in the ge-
neral population ranges from 6% to 17%, while even 38% 
of the population may be suffering from a mild form of the 
disease [3]. On average, the problem concerns 22% of men 
and 17% of women in all age groups [4]. In HypnoLaus — 
a study involving a large population (3,043 participants), 
conducted by Swiss researchers — the prevalence of mo-
derate and severe sleep-related breathing disorders (AHI 
≥ 15) reached 23.4% among women and 49.7% among 
men [5]. Young men suffer from the disorder 2–3 times 
more often than women, and the prevalence increases 
with age. Apart from age and the male sex, risk factors for 
OSA include obesity, neck circumference equal to or ex-
ceeding 43 cm in men and 40 cm in women, anatomical 
abnormalities of the facial skeleton and upper respiratory 
tract. Risk factors whose association with OSA is less pro-
ven include smoking and positive family history of sleep-
-related breathing disorders. Alcohol, hypnotic drugs and 
myorelaxants may exacerbate sleep-related breathing di-
sorders, but so far it has not been proven that they contri-
bute to the development of OSA. Greater prevalence than 
in the general population is also observed in some groups 
of patients, especially those suffering from congestive he-
art failure [6], hypertension [7], atrial fibrillation [8], type 
2 diabetes [9] and obesity, end-stage renal failure [10] as 
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complications, in whom moderate or severe OSA is suspec-
ted on the basis of their symptoms and history [16]. PSG, 
on the other hand, is the preferred method in patients with 
severe heart and lung diseases, neuromuscular diseases, 
insomnia and patients chronically taking opioids. Currently, 
portable devices are also not recommended for screening 
examinations or for examinations conducted in patients wit-
hout symptoms of OSA. A recently published meta-analysis 
of data [17] calls into question the sensitivity and clinical 
usefulness of all available methods of screening for OSA in 
asymptomatic patients. As of the date of writing this artic-
le, American Associations do not recommend conducting 
screening tests in patients without symptoms.
Examinations used in diagnostic evaluation of breathing 
disorders include:
 — classic PSG, supervised throughout the entire night and 
performed at a sleep lab;
 — unsupervised PSG with all channels necessary for the 
assessment of sleep structure and breathing;
 — examinations conducted with the use of instruments 
monitoring at least 3 physiological variables — respi-
ratory effort, airflow through the upper respiratory tra-
ct and blood oxygenation (including the above-mentio-
ned HSAT);
 — other examinations during which no more than two va-
riables are recorded.
Of the above examinations, only the classic, supervi-
sed PSG cannot be performed on an outpatient basis. The 
other ones can be also conducted at the patient’s home 
(PM, HSAT). The PSG examination is conducted at a dedi-
cated lab, where the patient stays overnight and is con-
tinuously supervised by the medical staff. PSG involves 
continuous, simultaneous observation and recording of 
various physiological processes occurring during sleep. It 
includes electroencephalography (EEG), electrooculography 
(EOG), electromyography (EMG), electrocardiography (ECG), 
respiratory flow tests, respiratory effort and blood oxygen 
saturation measurement. The examination currently con-
stitutes a gold standard for diagnosing OSA. It can also be 
used to appropriately select treatment parameters for con-
tinuous positive airway pressure (CPAP) therapy as well as 
for post-therapy follow-up.
Portable devices (PM, HSAT) monitoring one to seve-
ral parameters are also useful in OSA diagnostics. These 
devices usually differ in terms of their complexity and the 
amount of measured data, but they are united by common 
features that distinguish them from classic PSG, namely 
lower price as well as greater availability and convenien-
ce for the patient (no need to spend a night at a medical 
facility). They may constitute an alternative to PSG in the 
diagnosis of patients without severe complications, with 
medical history and symptoms indicating OSA. Diagnosis 
with the use of HSAT is also suggested for patients requi-
ring urgent diagnosis and prompt introduction of treatment 
when PSG is not available. According to the guidelines of 
AASM, portable devices which do not require the supervi-
sion of medical staff are sufficient to make diagnosis in pa-
tients in whom the probability of moderate and severe OSA 
is already high before the examination. A comprehensive 
evaluation of sleep, however, should still be conducted by 
a specialist. In addition, patients with severe comorbidities 
cannot be diagnosed with the use of the HSAT method [18].
In 2020, due to the widespread prevalence of OSA in 
the general population as well as the presumed large un-
derestimation of the problem, six major American associa-
tions dealing with sleep-related breathing disorders develo-
ped a document that attempted to standardize the nomen-
clature and juxtapose HSAT devices with the classic PSG 
as well as their place in contemporary diagnostic evalua-
tion of sleep-related breathing disorders and clinical trials 
[19]. According to experts, HSAT devices can be useful in 
diagnosing OSA. In clinical trials evaluating such devices, 
the profile of the studied patients should be as close as 
possible to the target group of patients that are likely to 
benefit from such diagnostics. Panel members also evalu-
ated what parameters should be measured by HSAT. They 
undoubtedly include saturation and nasal airflow or nasal 
cavity pressure, heart rate and respiratory effort measure-
ment. It was noticed, however, that the exact number and 
quality of measurement channels should depend on the 
clinical issue being examined. Each examination techno-
logy, if properly validated with PSG, may prove to be inde-
pendently effective in the diagnosis of specific breathing 
disorders during sleep.
OSA and cardiovascular diseases
Data from large epidemiological studies suggest that 
obstructive sleep apnoea constitutes and independently 
significant factor in the development and progress of such 
cardiovascular diseases as hypertension, heart failure, co-
ronary artery disease as well as various arrhythmias, inclu-
ding atrial fibrillation. Severe OSA increases the risk of both 
fatal and non-fatal cardiovascular incidents, especially in 
men. The risk is significantly reduced by CPAP therapy [20].
OSA simultaneously damages the cardiovascular sy-
stem through several mechanisms — mechanical, chemi-
cal and neurohumoral and as a result of an inflammatory 
response. Decreased intrathoracic pressure, hypoxia and 
arousal are the direct results of an increased respiratory 
drive in obstructed airways. “Negative” intrathoracic pres-
sure increases left atrial afterload, causes stretching of 
atrial walls and increases myocardial oxygen demand which 
can impair ejection fraction. It is believed that higher inci-
dence of atrial fibrillation in OSA patients is caused by the 
effect on the mechanoreceptors of atrial walls as well as 
stretching of the walls. Reflex increase in the sympathetic 
nervous system tension causes an increase in myocardial 
94
Folia Cardiologica 2021, vol. 16, no. 2
www.journals.viamedica.pl/folia_cardiologica
oxygen demand during impaired gas exchange and hypo-
xemia, which may cause symptoms of myocardial ischae-
mia. OSA is also associated with increased oxidative stress 
and initiation of vascular endothelium-related inflammato-
ry cascade [21]
Observational studies using both PSG and portable 
devices showed that OSA is more prevalent among heart 
failure patients with impaired ejection fraction than in the 
general population (53% vs. 12%) [6]. Cardiac systolic dys-
functions correlate with the degree of OSA, and more com-
monly occur in a moderate or severe form. It is an interes-
ting observation that in the case of OSA and heart failure 
patients the diurnal symptoms of OSA are less severe and 
the ESS scale is not very useful. Data on patients with he-
art failure and preserved fraction are less available. On the 
other hand, observational studies proved that CPAP therapy 
with constant pressure reduced sympathetic activity, blood 
pressure as well as ESS scores and improved left ventricu-
lar systolic function, which may indirectly reduce the risk 
of readmission to hospital and death [6].
The risk of nocturnal myocardial ischaemia is increa-
sed in patients with severe OSA. Breathing disorders and 
significant desaturation almost double the risk of sudden 
cardiac death, regardless of other risk factors. OSA pa-
tients most often die of sudden cardiac death between 
midnight and 6 am [21]. Evidence from epidemiological 
studies indicate that apart from having an impact on the 
risk factors for ischaemic heart disease (hypertension, 
atherosclerosis), OSA may also be an independent risk 
factor for coronary artery disease [22]. The exact mecha-
nism of the phenomenon has not been explained yet, but 
inflammatory aetiology seems most likely. It is estimated 
that mild, moderate and severe OSA occurs in, respecti-
vely, 69%, 43% and 25% of patients with acute coronary 
syndrome [23]. Therefore, it seems legitimate to conduct 
diagnostics in this group of patients, given the fact that 
the prognosis is worse if OSA is left untreated [24]. A re-
cent study involving more than 1,000 patients with advan-
ced coronary artery disease eligible for coronary artery 
bypass grafting (CABG) [25] also showed that moderate 
and severe OSA was common, occurring in 50.9% of in-
dividuals in this group of patients. The study also proved 
that in patients with coronary artery disease, OSA was an 
independent factor contributing to major cardiovascular 
events, including death.
Another study was published in 2018. It was a meta-
-analysis within the framework of which major adverse car-
diac events (MACE), including death from cardiovascular 
causes, myocardial infarction, brain stroke, repeated need 
for coronary revascularization as well as hospitalizations 
due to heart failure, were evaluated as endpoints [26]. 
Nine studies, including 2 randomized ones, were analy-
sed. In observational studies, CPAP therapy was associa-
ted with a significantly lower risk of MACE, but these data 
were not confirmed in randomized studies. Treatment of 
OSA patients with concomitant coronary artery disease can 
potentially decrease the risk of recurrence of a cardiova-
scular event, but the role of CPAP in secondary prevention 
of myocardial infarction is currently being debated due to 
the lack of expected results in randomized studies [27]. 
Results of the SAVE study, published in 2016 [28], even 
suggest that CPAP therapy reduces the intensity of sno-
ring, drowsiness during the day and improves the quality 
of life and mood, but has no grater impact on the risk of 
cardiovascular events than standard medical care. These 
doubts can only be resolved after conducting extensive epi-
demiological studies concerning the occurrence of OSA in 
patients with coronary artery disease.
Numerous studies conducted over the years in Europe, 
the United States and Australia proved that OSA was as-
sociated with the development of hypertension. Through 
the above-mentioned mechanisms, apnoea and hypoxia 
cause activation of the sympathetic system and spikes in 
blood pressure, which over time progress to chronic hyper-
tension. In a prospective study involving participants of the 
Wisconsin Sleep Cohort Study, it was shown after a 4-ye-
ar-long observation period, which included the impact of 
age, sex, body build as well as the use of such stimulants 
as alcohol and cigarettes, that patients with moderate and 
severe OSA were, respectively, two and three times more 
likely to develop hypertension than healthy persons [7]. 
Thus, OSA constitutes an independent factor for the deve-
lopment of hypertension, and the degree of the respiratory 
disorder correlates with the risk of hypertension. Patients 
with resistant hypertension, who represent up to a dozen 
or so percent of patients with diagnosed hypertension, 
are at a particularly high risk of OSA. Given the number of 
patients with hypertension in Poland, there may be up to 
one million individuals with resistant hypertension requi-
ring diagnosis and treatment of OSA.
Arrhythmias are another pathology associated with OSA. 
Studies using PSG showed that patients with obstructive 
sleep apnoea experienced nocturnal arrhythmias more of-
ten than individuals who do not suffer from this disease. It 
is estimated that the incidence of atrial fibrillation is approx. 
4.8% higher in OSA patients than in the general population 
[8]. It seems that diagnosis for respiratory disorders sho-
uld also be conducted in this group of patients. According 
to data from randomized studies, the mean HR values and 
the number of premature ventricular contractions during 
sleep were lower in patients undergoing CPAP therapy due 
to OSA. The application of CPAP therapy is also associated 
with a significant reduction in atrial fibrillation recurren-
ce, even after ablative treatment or electric cardioversion 
[29]. In a 2015 meta-analysis of data it was proven that the 
application of CPAP therapy in patients who had undergo-
ne an intervention due to atrial fibrillation reduced the risk 
of AF recurrence by 44% [30]. OSA is currently believed to 
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be a risk factor for AF recurrence and the implementation 
of OSA diagnostics is recommended in secondary preven-
tion of this arrhythmia [31]. In recent years it has also been 
observed that various cardiovascular diseases leading to 
the need for pacemaker implantation are associated with 
the concomitant presence of undiagnosed OSA. In a mul-
ticentre study involving patients with pacemakers implan-
ted due to cardiomyopathy, atrioventricular blocks or sinus 
node diseases all patients were initially unaware of the fact 
that they suffered from sleep-related breathing disorders. 
Based on PSG, obstructive apnoea during sleep was ob-
served in as many as 59% of patients, and in over 21% of 
those patients AHI exceeded 30 [32]. It shows how com-
mon sleep-related breathing disorders are among cardiac 
patients and how often they can remain undiagnosed by 
attending physicians.
Currently, patients in Poland are referred for PSG on 
the basis of symptoms of sleep-related breathing disor-
ders as well as data from medical history. The examina-
tion is also recommended in particular disease entities, 
for example in the case of resistant hypertension and se-
condary prevention of atrial fibrillation in patients with risk 
factors. OSA is also ruled out within the framework of the 
diagnostic and certification process qualifying professio-
nal drivers and driving licence applicants who experien-
ce symptoms of the disease or have a suggestive history. 
A doctor specializing in sleep medicine — usually a pulmo-
nary specialist — verifies whether patients are eligible for 
such an examination. The examination of sleep-related 
breathing disorders has not been directly included in the 
guidelines for diagnostics and treatment of the above-de-
scribed cardiovascular diseases, except for resistant hy-
pertension and secondary prevention of atrial fibrillation. 
However, taking into account only patients suffering from 
this disease (estimated at 12–16% of all hypertensive pa-
tients), more than one million potential patients can bene-
fit from PSG. Apart from that, there are also patients with 
other cardiovascular diseases as well as non-cardiac pa-
tients and examinations conducted within the framework 
of post-treatment follow-up. For economic reasons alone, 
it is virtually impossible to conduct so many PSG in our 
health care system. However, portable devices and HSAT 
systems can help. These solutions are cheaper, more re-
adily available and more convenient for patients. Clinical 
studies also confirm that despite being slightly less sens-
itive, HSAT devices are much more cost-effective [33] and 
can be successfully used for diagnosing OSA. Given the 
fact that it is not possible to refer a large number of pa-
tients for PSG, portable devices seem to be the future of 
sleep-disordered breathing diagnostics.
Obstructive sleep apnoea is both the cause and a com-
mon denominator of many cardiovascular diseases. Current 
knowledge of this condition indicates that it is underdiag-
nosed in and the availability of diagnostics and specialist 
treatment is poor. At this point it seems that the main cau-
se of the above problems in our health care system is the 
lack of standardization of readily available and inexpensive 
diagnostic devices that can unburden specialized health 
care. Devices using modern technologies to detect sleep-
-related breathing disorders are already available in the 
market. An example can be Clebre — a wireless acoustic 
sensor monitoring sleep-related breathing disorders, which 
continuously analyses recordings of auscultatory phe-
nomena with the use of artificial intelligence algorithms 
[34]. The device can be used at home and does not have 
to operated by medical staff. Results of the examination 
can be sent to the physician immediately after its comple-
tion. Nevertheless, further population studies evaluating 
the effectiveness of such tools as CLEBRE in screening 
for OSA in specific subpopulations of cardiac patients and 
others are still needed in order to increase the number of 
diagnosed OSA cases.
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